Navigation Links
Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Date:2/10/2010

SAN DIEGO, Feb. 10 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma.  Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

"Our data shows that in mice deficient for the LPA1 receptor, there is dramatic protection from the bleomycin-induced skin fibrosis seen in normal mice," said Dr. Tager, a member of Amira's Scientific Advisory Board.  "In addition, similar protection from fibrosis was observed in normal mice treated with Amira's LPA1 receptor antagonist, AM095."

Peppi Prasit, Ph.D., Chief Scientific Officer, said, "AM095 is an orally available, potent and selective antagonist of the LPA1 receptor.  We are currently moving AM095 and AM152, another LPA1 antagonist, through GLP toxicology testing and expect to initiate human clinical studies in the second half of 2010."

Bob Baltera, Chief Executive Officer, added, "So far we have seen compelling data in numerous preclinical models of fibrosis.  We are excited by the possibility of eventually exploring efficacy in human disease settings, such as idiopathic pulmonary fibrosis, scleroderma, kidney and liver fibrosis, and various metastatic cancers. There is a lot of work to be done
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
2. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
3. ISTA Pharmaceuticals Announces 2010 Financial Guidance
4. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
5. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
6. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
7. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
8. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
9. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
10. Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 The ... the five years to 2014. Industry operators were able ... during the period, as well as establish distribution contracts ... due in large part to its novelty; energy drinks ... in that time, industry operators have been able to ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... for the 2014 NEXT Awards in the Technology ... has been selected as the sole female finalist ... Chamber of Commerce and the Nashville Entrepreneur Center ... accomplishments of companies and individual entrepreneurs in five ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Buoyed by technological advancements, surgical techniques, and ... become the preferred treatment for several chronic diseases ... liver. Advancements in organ and tissue transplantation have ... patients. Organ transplant today represents a ...
(Date:9/19/2014)... researchers at the University of Utah School of Medicine ... of mitochondria in debilitating and fatal motor neuron diseases ... such illnesses. , Researchers led ... when healthy, functioning mitochondria was prevented from moving along ... neurons mice developed symptoms of neurodegenerative diseases. In ...
(Date:9/19/2014)... grow well in infertile land, and bear many beans ... is because most legumes have a symbiotic relationship with ... air and then supply the host plant with ammonia ... organs called nodules in their roots. However, if too ... the growth of the plants, because the energy cost ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Long-distance communication from leaves to roots 2
... June 29 Medicsight PLC, a subsidiary of MGT Capital ... industry leader in the development of Computer-Aided Detection (CAD) and ... of disease, is pleased to announce the launch of its ... benefits of Medicsight,s ColonCAD software truly accessible to all radiologists ...
... , LONDON, June 29 The Healthcare Group at ... Quarterly Analyst Briefing Presentation on the European Hospital Information Systems ... at 2 p.m. GMT. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... some kind of information system in place, only a few ...
... Clarient, Inc. (Nasdaq: ... services resource for pathologists, oncologists and the pharmaceutical industry, today announced ... Index when Russell Investments reconstitutes its comprehensive set of U.S. and ... of additions posted June 12 on www.russell.com . ...
... ... your pet healthy and happy and is more likely to avoid serious and costly health problems ... ... health care can prevent expensive vet bills in the future, pet owners are reminded, as everyone continues ...
... Florida,s First Certified Urgent ... County Florida has become the first in the State to receive formal recognition as a Certified ... ... Care Medical Centers of Palm Beach County Florida has become the first in the State to ...
... ... to access critical health data stored in electronic health records (EHRs). The company has just ... , ... 29, 2009 -- Orion Health , a market leader in providing clinical workflow and ...
Cached Medicine News:Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 2Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 3Health News:Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value 2Health News:Clarient Set to Join Russell 3000 Index 2Health News:Clarient Set to Join Russell 3000 Index 3Health News:Clarient Set to Join Russell 3000 Index 4Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 2Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 3Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 2Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 3
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
Medicine Products: